Royalty Report: Medical, Supply, Wound Care – Collection: 27675

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 11

Primary Industries

  • Medical
  • Supply
  • Wound Care
  • Device
  • Surgical
  • Disease
  • Orthopedic
  • Drugs
  • Biotechnology
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27675

License Grant
The agreement licensed certain bone wax rights to develop products in the field of bone remodeling, based on patent number 7,074,425 for use in the human skeletal system.  The license agreement excludes the fields of (1) a resorbable hemostat (resorbable bone wax), (2) a resorbable orthopedic hemostat (bone wax) and antimicrobial dressing, and (3) veterinary orthopedic applications. In January 2014, Licensee received 510k approval for their first product under the license, a bioactive bone graft putty and bone graft extender.  In February 2014, Licensor granted a Commercial License to Licensee according to the terms of the development and license agreement.
License Property
The Licensor acquired patent 7,074,425 in September 2009.  It is for a resorbable bone wax and delivery system for orthopedic bone void fillers. The patent offers innovative, safe and effective resorbable orthopedic products that are complementary to the already existing Licensor products.  The bone wax and delivery system address issues such as bone wax granuloma and the cost-effective delivery of materials that manage bone wound healing. The resorbable orthopedic products covered by the patent are (a) a resorbable orthopedic hemostat (resorbable bone wax) used to stop blood flow, (b) a delivery system for osteogenic/osteoinductive orthopedic products (bone void fillers), and (c) the formula as a delivery system for bone growth factors.

IPSCIO Record ID: 72974

License Grant
The agreement licensed certain bone wax rights to develop products in the field of bone remodeling, based on patent number 7,074,425 for use in the human skeletal system.
Field of Use
The field of use is bone remodeling in the human skeletal system.  The license agreement excludes the fields of (1) a resorbable hemostat (resorbable bone wax), (2) a resorbable orthopedic hemostat (bone wax) and antimicrobial dressing, and (3) veterinary orthopedic applications.

IPSCIO Record ID: 287764

License Grant
Under the terms of this agreement, the Company recognizes royalty revenue on sales of products containing the Companys patented resorbable bone hemostasis.
License Property
The Companys products are primarily purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds.
Field of Use
Licensed refers to certain bone wax rights to Licensee to develop products in the field of bone remodeling, based on Resorbable’s patent number 7,074,425 (see Note 9 “Intangible Assets”) for use in the human skeletal system.

The Company’s business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.

IPSCIO Record ID: 226071

License Grant
The Company assumed an exclusive license agreement with an undisclosed Licensee for bioactive bone graft putty.
License Property
Bioactive bone graft putty is an FDA cleared bioactive synthetic bone graft substitute comprised of a mixture of calcium phosphate granules and bioglass granules suspended in a resorbable polymer carrier that facilitates handling and delivery of the granule components to fill spaces of missing bone. The product is indicated as a bone void filler for standalone use in posterolateral spine fusion procedures without the aid of autologous extenders or enhancers to meet the needs of the surgeon and effectively facilitate structural fusion of the spine. The ratio of certain components in Signafuse’s composition is similar to ratios found to promote attachment and bone formation to produce a stable scaffold that allows sustained bioactivity and osteoconductivity during the healing process. The patented bioactive component is designed for a faster rate of bone fill than bioglass particles with a broader size range. In vitro studies have demonstrated the product’s effective phosphate layer formation on the surface of the implant as early as seven days after application.

IPSCIO Record ID: 5290

License Grant
The Licensee entered into a five-year license agreement with Licensor relative to a technology known as OPLA. The Licensee and Licensor are committed to research and development of specified uses of the OPLA technology.
License Property
The Open-cell Polylactic Acid or OPLA is a porous polymer foam technology, and to our biomaterials technology platform in the orthopedics drug and delivery markets.  This porous tissue matrix technology facilitates wound healing in both bone and soft tissue and is bio absorbable at controlled rates for specific functions and tissues.  This technology adds a series of products, development programs and intellectual property related to porous biodegradable regeneration matrices.  Specifically, we are researching applications for articular cartilage regeneration, bone growth scaffolds for spinal and trauma applications and for the delivery of drugs and growth factors.

IPSCIO Record ID: 253964

License Grant
The Parties desire to develop and commercialize an Additional Product, as a product line extension of Licensees proprietary synthetic bioactive bone grafting material known as VITOSS.

The Parties designate BioActive VITOSS FOAM as an Initial Product.

The original agreement is exclusive.

License Property
Initial Products shall mean any one or combination of Hot Pockets  comprised of Licensees VITOSS product wrapped or otherwise incorporated in porous, bioresorbable material developed by Licensor; bioresorbable dough based on Licensees VITOSS in combination with other resorbable materials developed by Licensor;  bioresorbable haste based on Licensees VITOSS in combination with other resorbable materials developed by Licensor;  CorticoCancellous Products; and  BioActive VITOSS FOAM, in each case utilizing the respective Intellectual Property of both Parties, and as developed and manufactured by the parties pursuant to this Agreement.

'BioActive VITOSS FOAM' shall mean VITOSS, combined with BioActive Ceramic Material and fibrous bovine collagen.'

Field of Use
The field of use is synthetic bioactive bone grafting.

IPSCIO Record ID: 26284

License Grant
The University granted an exclusive license to several of its patents covering, among other things, enhanced Nell-1 bone mineralization. Under the license, the Licensee is permitted to make, have made, use, sell, offer for sale and import any products covered by the licensed patents in a certain field of use.
License Property
The Licensee is targeting spinal fusion as the first clinical indication and is currently in the pre-investigational device exemption (IDE) phase. The lead product, purified Nell-1 recombinant protein, is expected to be dried onto ß-tricalcium phosphate (TC”) bone void filler to produce a medical device, known as Nell-1/TCP (Nell/TCP Fusion Device). This device will be mixed with 510(k) cleared DBX® Demineralized Bone Putty recommended for use in conjunction with a cleared intervertebral body fusion device. The Nell-1/TCP Fusion Device is intended for use in lumbar spinal fusion and may have a variety of other applications such as cervical spinal fusion.
Field of Use
By a subsequent Seventh Amendment entered into on August 7, 2012, the parties modified the applicable field of use that Licensee is permitted to use the patents in, which generally comprises musculoskeletal repair and regeneration, plus some related methods of manufacture. The Nell-1/TCP Fusion Device will be comprised of a single dose vial of NELL-1 recombinant protein freeze dried onto TCP. A vial of Nell-1/TCP will be sold in a convenience kit with a diluent and a syringe of 510(k) cleared demineralized bone (“DBX® Putty”), produced by MTF. A delivery device will allow the surgeon to mix the reconstituted Nell 1/TCP with the appropriate quantity of DBX® Putty just prior to implantation.

IPSCIO Record ID: 253984

License Grant
Licensor grants:
—  an exclusive license under the Licensed Technology, CoStasis Ingredient Improvements and CoStasis Ingredient Improvement Patents to make, have made, sell, have sold, offer for sale, export, have exported, import and have imported CoStasis Products in the Orthopedic Hemostat Field in the Territory;

—  until such time as Licensor elects to distribute, promote, market and/or sell one or more Licensor Branded CoStasis Products, an exclusive license under the Licensed Technology, CoStasis Ingredient Improvements and CoStasis Ingredient improvement Patents to make, have made, sell, have sold, offer for sale, export, have exported, import and have imported CoStasis Products in the Non-Orthopedic Hemostat Field in the Territory,

—  from and after such time as Licensor elects to distribute, promote, market and/or sell one or more Licensor Branded CoStasis Products, a coexclusive, meaning that only the Parties can act in each country of the Territory, license under the Licensed Technology, CoStasis Ingredient Improvements and CoStasis Ingredient Improvement Patents to make, have made, sell, have sold, offer for sale, export, have exported, import and have imported CoStasis Products in the Non-Orthopedic Hemostat Field in the Territory;

—  a non-exclusive license under the Licensed Technology to make, have made, use, sell, have sold, offer for sale, export, have exported, import and have imported CellPaker Products and Accessories in the CellPaker Field in the Territory; and

—  a non-exclusjve license under the Licensed Technology and CoStasis Ingredient improvements and CoStasis Ingredient Improvement Patents to use, including, without limitation, to research, have researched, develop and have developed) CoStasis Ingredients and Formulated CoStasis Ingredients, but only for uses directly related to Licensees Product licenses and rights hereunder, Products, other than Licensor Branded CoStasis Products, and Accessories in the Licensed Field in the Territory.

License Property
CoStasis Ingredients means collagen and thrombin.

CoStasis® Surgical Hemostat product is a sterile suspension of bovine collagen and bovine thrombin in calcium chloride.

CoStasis Product means a product containing the Formulated CoStasis Ingredients in a syringe.

CellPaker® Plasma Collection Svstem is a needleless syringe device for drawing blood from a human for direct placement into a centrifuge for centrifuging to separate plasma from red and white blood cells.

CellPaker Product means a CellPaker® Plasma Collection System product for use with CoStasis Products, CoStasis Ingredients' means collagen and thrombin.

Field of Use
Licensed Field means, collectively or individually, as the context requires,
(a) the Orthopedic Hemostat Field;
(b) the Non-Orthopedic Hemostat Field; and
(c) the CellPaker Field.

The terms Licensed Field, Orthopedic Hemostat Field and Non-Orthopedic Hemostat Field are expressly inapplicable to Drug-Loaded Products, even if a Drug-Loaded Product is approved for human use in the Licensed Field.

CellPaker Field means human medical uses of the CellPaker Products and/or Accessories in connection with CoStasis Products.

Non-Orthopedic Hemostat Field means, with respect to a CoStasis Product, human medical uses of the CoStasis Product as a Hemostat for all indications, other than indications within the Orthopedic Hemostat Field.

Orthopedic Hemostat Field means, with respect to a CoStasis Product, human medical uses of the CoStasis Product as a Hemostat for all indications treated by an orthopedic surgeon or other surgeon relating to the surgical repair of diseases or injuries of the spine, bone or related soft tissue, such as ligaments or cartilage.

IPSCIO Record ID: 711

License Grant
Related to a certain asset purchase agreement  the Licensee will acquire substantially all of the assets of the Company, and this Agreement is a component of the Purchase Price for the Assets.  The assets include US Patent 7074425 and products that are developed from or otherwise utilize any of the patented technology acquired.

IPSCIO Record ID: 5492

License Grant
LICENSOR hereby grants to LICENSEE, to the extent of the LICENSED FIELD and LICENSED TERRITORY, a license under PATENTS, to fully practice PATENTS, including the right to make, use, offer for sale, sell and import PRODUCTS and promote the methods and compositions recited in the claims of PATENTS using PRODUCTS in the LICENSED FIELD.
License Property
The U.S. and foreign issued patents relates to platelet-based growth factors (used in platelet rich plasma gel used in wound care in the specific field of use covering diagnostic and therapeutic spinal, neurosurgery and orthopedic surgery. U.S. Patent No. 5,165,938 entitled “Wound Healing Agents,” issued 11/24/92.
Field of Use
SCHEDULE OF PRODUCTS
SEPARATORS
2760-40-101       Disposable Processing Kit – Single
2760-40-102       Disposable Processing Kit – Double

Disposable Processing Kits contain the items required for containing blood during processing in the centrifuge

CAPITAL
2760-40-000       Centrifuge
2760-40-310       Centrifuge and Cart Assembly

APPLICATORS/ MIXERS
2760-40-200       Applicator Kit

IPSCIO Record ID: 27224

License Grant
The Company has committed to pay royalties to various undisclosed Licensors on the sale of products or components of products developed under certain product development and licensing agreements.
Field of Use
Proprietary products and services are for the orthopedic health care market. The Company’s product lines includes bone growth stimulation devices, CPM devices and ancillary orthopedic recovery products, and Hyalgan, a therapeutic injectable. All the Company’s products focus on improving the clinical outcomes and cost-effectiveness of orthopedic procedures.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.